CNBX (CNBX Pharmaceuticals) Total Liabilities : $2.54 Mil (As of Nov. 2024)

View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals Total Liabilities?

CNBX Pharmaceuticals's Total Liabilities for the quarter that ended in Nov. 2024 was $2.54 Mil.

CNBX Pharmaceuticals's quarterly Total Liabilities declined from May. 2024 ($2.53 Mil) to Aug. 2024 ($2.51 Mil) but then increased from Aug. 2024 ($2.51 Mil) to Nov. 2024 ($2.54 Mil).

CNBX Pharmaceuticals's annual Total Liabilities increased from Aug. 2022 ($2.44 Mil) to Aug. 2023 ($2.52 Mil) but then declined from Aug. 2023 ($2.52 Mil) to Aug. 2024 ($2.51 Mil).

CNBX Pharmaceuticals Total Liabilities Historical Data

The historical data trend for CNBX Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals Total Liabilities Chart

CNBX Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Total Liabilities

Get a 7-Day Free Trial

0.46

1.27

2.44

2.52

2.51

CNBX Pharmaceuticals Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24
Total Liabilities	Get a 7-Day Free Trial															2.48	2.52	2.53	2.51	2.54

CNBX Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CNBX Pharmaceuticals's Total Liabilities for the fiscal year that ended in Aug. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.511	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2.51

Total Liabilities	=	Total Assets (A: Aug. 2024 )	-	Total Equity (A: Aug. 2024 )
	=	0.031	-	-2.48
	=	2.51

CNBX Pharmaceuticals's Total Liabilities for the quarter that ended in Nov. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.537	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2.54

Total Liabilities	=	Total Assets (Q: Nov. 2024 )	-	Total Equity (Q: Nov. 2024 )
	=	0.022	-	-2.514
	=	2.54

CNBX Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CNBX Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814

Website

https://www.cnbxpharma.com

CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.

Executives

Cannabics Inc.	10 percent owner	108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills	director, officer: President, CEO, CFO
North American Mining Corp	10 percent owner	6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford	director, officer: Vice-President, Secretary